Modality
Gene Editing
MOA
PD-L1i
Target
APOC3
Pathway
RAS/MAPK
Ewing Sarcoma
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
~Jan 2019
→ ~Apr 2020
NDA/BLA
Jul 2020
→ Apr 2028
NDA/BLACurrent
NCT05159327
2,942 pts·Ewing Sarcoma
2020-07→2028-04·Recruiting
2,942 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-113w agoConference· Ewing Sarcoma
2028-04-152.0y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
NDA/BLA
Recruit…
Catalysts
Conference
2026-03-11 · 3w ago
Ewing Sarcoma
Ph3 Readout
2028-04-15 · 2.0y away
Ewing Sarcoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05159327 | NDA/BLA | Ewing Sarcoma | Recruiting | 2942 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |